Showing 1801-1810 of 7669 results for "".
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people …
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic patients), Mr. Atesh Chandra (customer service: The Breake…
- Makucell Unveils Renewnthttps://practicaldermatology.com/news/20120627-makucell_unveils_renewnt/2459779/Makucell, Inc., a pioneering regenerative biotechnology company, recently released the Renewnt (pronounced “Re-new-int”) brand. Renewnt's proprietary ingredient, Asymmtate, is a new approach to cellular aging, optimizing signals in the Wnt (pronounced “wint”) pathway. Optimal signaling stimulates t…
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=3…
- Merz Appoints New Vice President of Medical Dermatologyhttps://practicaldermatology.com/news/20120611-merz_appoints_new_vice_president_of_medical_dermatology/2459786/Merz, Inc. has appointed James P. Hartman as Vice President of Medical Dermatology. In the new role, Hartman will be responsible for the company's Medical and OTC/OTX dermatology business unit, which includes Naftin® (naftifine hydrochloride) and Mederma®. Prior to joining Merz, Hartman was Vice Pr…
- Psoriasis Genetic Map Explored by International Psoriasis Councilhttps://practicaldermatology.com/news/20120607-psoriasis_genetic_map_explored_by_international_psoriasis_council/2459788/The International Psoriasis Council (IPC) is leading the effort to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis. Their report in the British Journal of Dermatology's June edition outlines the remarkable progress…
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared …
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and BRAF Inhibitors versus dabrafenib) trial is a Phas…
- Merz Realignment Focuses on Synergieshttps://practicaldermatology.com/news/20120518-merz_realignment_focuses_on_synergies/2459796/Merz is realigning and integrating its core businesses in the United States and Canada into one organization, with a single leadership team, the company announced. According to Merz, "the newly aligned structure is designed to strengthen the company's growth potential and to ensure Merz provides th…
- Merz CEO Focused on Advancing the Companyhttps://practicaldermatology.com/news/20120515-merz_ceo_focused_on_advancing_the_company/2459801/William “Bill” Humphries, newly appointed CEO of Merz, Inc., has been setting the record straight. For example, addressing a recent injunction that bars the marketing of Xeomin for aesthetic indications, he insists, “the impact of the injunction isn't dramatic.” As a private company with more than …